In Brief: Immune Response
Immune Response: Regains "all manufacturing, marketing and distribution rights" for the "Salk" HIV immunotherapeutic vaccine from former joint venture partner Rhone-Poulenc Rorer. A total of $55 mil. was committed to the development program under the 50/50 joint venture, Immunization Products Ltd. Under the negotiated settlement, RPR "will not provide additional funds" and will receive residual royalties of up to $3 mil. should the product be marketed. The settlement follows 1994 arbitration proceeding under which Immune Response regained control of regulatory submissions and clinical trials. Immune Response says it will be actively looking for a pharmaceutical marketing partner. An FDA advisory committee recently gave the go-ahead recommendation for Phase III trials of the vaccine based primarily on safety data ("The Pink Sheet" Jan. 30, p. 3)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth